Trial Outcomes & Findings for Weight Loss and Exercise for Communities With Arthritis in North Carolina (NCT NCT02577549)
NCT ID: NCT02577549
Last Updated: 2023-06-27
Results Overview
To determine whether a pragmatic, community-based, 18-month diet-induced weight-loss and exercise intervention implemented in three North Carolina counties with diverse residential (from urban to rural) and socioeconomic composition significantly decreases knee pain \[as measured by the Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain subscale\] in overweight and obese adults with knee Osteoarthritis (OA) compared to an attention-control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations - The WOMAC measures five items for pain (score range 0-20). Measure Description: Range, 0 to 20 (0, no pain; 2 to 8, mild; \>8 to 14, moderate; and \>14 to 20, severe); between-group MCID = 1.6, calculated as half the SD.
COMPLETED
NA
823 participants
18 months
2023-06-27
Participant Flow
We used overlapping recruitment strategies. A combination of mailings, local newspaper ads, and direct targeting through electronic health records were used. We also had strong ties with local aging service networks and access to senior centers, senior high-rise residential sites, churches, and a large database of older adults who signed consent to be contacted about participating in future clinical trials.
Participant milestones
| Measure |
Diet & Exercise
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
|
Attention Control
The attention control intervention covered an 18-month period delivered in five
1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
|
|---|---|---|
|
Overall Study
STARTED
|
414
|
409
|
|
Overall Study
COMPLETED
|
336
|
332
|
|
Overall Study
NOT COMPLETED
|
78
|
77
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Weight Loss and Exercise for Communities With Arthritis in North Carolina
Baseline characteristics by cohort
| Measure |
Diet & Exercise
n=414 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=409 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
Total
n=823 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
64.5 years
STANDARD_DEVIATION 7.8 • n=5 Participants
|
64.7 years
STANDARD_DEVIATION 7.8 • n=7 Participants
|
64.6 years
STANDARD_DEVIATION 7.8 • n=5 Participants
|
|
Sex: Female, Male
Female
|
320 Participants
n=5 Participants
|
317 Participants
n=7 Participants
|
637 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
94 Participants
n=5 Participants
|
92 Participants
n=7 Participants
|
186 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
7 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
407 Participants
n=5 Participants
|
401 Participants
n=7 Participants
|
808 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
111 Participants
n=5 Participants
|
116 Participants
n=7 Participants
|
227 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
289 Participants
n=5 Participants
|
281 Participants
n=7 Participants
|
570 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
11 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Womac pain score
|
7.5 score on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants
|
7.5 score on a scale
STANDARD_DEVIATION 3.3 • n=7 Participants
|
7.5 score on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants
|
PRIMARY outcome
Timeframe: 18 monthsPopulation: A total of 13 persons (7 in D\&E and 6 in attention control) did not complete this testing measure but completed other measures.
To determine whether a pragmatic, community-based, 18-month diet-induced weight-loss and exercise intervention implemented in three North Carolina counties with diverse residential (from urban to rural) and socioeconomic composition significantly decreases knee pain \[as measured by the Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) pain subscale\] in overweight and obese adults with knee Osteoarthritis (OA) compared to an attention-control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations - The WOMAC measures five items for pain (score range 0-20). Measure Description: Range, 0 to 20 (0, no pain; 2 to 8, mild; \>8 to 14, moderate; and \>14 to 20, severe); between-group MCID = 1.6, calculated as half the SD.
Outcome measures
| Measure |
Diet & Exercise
n=329 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=316 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Knee Pain
|
5.0 score on a scale
Interval 4.6 to 5.4
|
5.5 score on a scale
Interval 5.1 to 5.9
|
SECONDARY outcome
Timeframe: 18 monthsPopulation: Not all persons completing the study completed this measure at follow up.
To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves WOMAC self-reported function in overweight and obese adults with knee OA compared to an attention control group - test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4) - Higher scores on the WOMAC indicate more pain, stiffness, and functional limitations. The WOMAC function score is a total of seventeen items for function (total score range 0-68). Measure Description: Range, 0 to 68 (0, no difficulty; 68, extreme).
Outcome measures
| Measure |
Diet & Exercise
n=325 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=311 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Function
|
16.5 score on a scale
Interval 15.3 to 17.7
|
19.8 score on a scale
Interval 18.6 to 21.0
|
SECONDARY outcome
Timeframe: 18 monthsPopulation: Not all persons completing the study completed this measure at follow up.
To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves health-related quality of life as measured by the physical subscale of the SF-36 questionnaire in overweight and obese adults with knee OA compared to an attention control group - Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state - The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
Outcome measures
| Measure |
Diet & Exercise
n=321 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=306 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Health Related Quality of Life (SF-36) Physical Subscale
|
41.4 score on a scale
Interval 40.2 to 42.6
|
37.6 score on a scale
Interval 36.3 to 38.8
|
SECONDARY outcome
Timeframe: 18 monthsPopulation: Not all persons completing the study completed this measure at follow up.
To determine whether a pragmatic, community-based, 18-month, diet-induced weight-loss and exercise intervention improves 6-minute walk distance (an accepted measure of mobility) in overweight and obese adults with knee OA compared to an attention control group.
Outcome measures
| Measure |
Diet & Exercise
n=247 Participants
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=219 Participants
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Mobility (Six Minute Walk)
|
419 meters
Interval 411.0 to 428.0
|
376 meters
Interval 368.0 to 385.0
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 18 monthsPopulation: Currently only data for the primary outcome and some of the secondary outcomes have been analyzed and published. Additional analyses are being conducted. The cost effectiveness outcome measure will be available to report in the coming months.
To establish the cost-effectiveness of this pragmatic, community-based, multimodal diet-induced weight-loss and exercise program by conducting cost-effectiveness and budgetary impact analyses using data from the current trial in a validated computer-simulated model of knee OA.
Outcome measures
Outcome data not reported
Adverse Events
Diet & Exercise
Attention Control
Serious adverse events
| Measure |
Diet & Exercise
n=414 participants at risk
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=409 participants at risk
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Injury, poisoning and procedural complications
Car Accident
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Injury, poisoning and procedural complications
Fall
|
0.24%
1/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Injury, poisoning and procedural complications
Surgery Complications
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Injury, poisoning and procedural complications
Burn
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Injury, poisoning and procedural complications
Ruptured Blood Vessel
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Gall Bladder Surgery
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Bariatric Surgery
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Hip Replacement
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.73%
3/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Cardiac Monitor
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Other Knee Surgery
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Knee replacement
|
4.1%
17/414 • Number of events 19 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
5.6%
23/409 • Number of events 23 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Hernia Surgery
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Knee Amputation
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Laminectomy
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Oophorectomy
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Throat Surgery
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Appendectomy
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Cardiac Ablation
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Hysterectomy
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Intestinal Blockage Surgery
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Neck Surgery
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Shoulder Replacement Surgery
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Nervous system disorders
Numbness/Tingling
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Nervous system disorders
Fainting/Dizziness
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Nervous system disorders
Vertigo
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Psychiatric disorders
Mood Alteration
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Metabolism and nutrition disorders
Low Blood Sodium
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Atrial Fibrillation
|
0.97%
4/414 • Number of events 4 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.98%
4/409 • Number of events 5 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Chest Pain
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.98%
4/409 • Number of events 4 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Stroke
|
1.2%
5/414 • Number of events 5 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Heart Attack
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
TIA
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Congestive Heart Failure
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
AV Heart Block
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Blood Clot
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Bradycardia & Hypertension
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Cardiac disorders
Pulmonary Embolism
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Gastrointestinal disorders
Bowel Obstruction
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Gastrointestinal disorders
Ulcer
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Gastrointestinal disorders
Diverticulitis
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Gastrointestinal disorders
Ketoacidotic Coma
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Renal and urinary disorders
UTI
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Renal and urinary disorders
Colovesical Fistulitis
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Renal and urinary disorders
Enlarged Prostate
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Renal and urinary disorders
Cyst
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Renal and urinary disorders
Impaired Kidney Function
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Blood and lymphatic system disorders
Cancer
|
1.7%
7/414 • Number of events 7 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
2.2%
9/409 • Number of events 9 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Blood and lymphatic system disorders
Tumor
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Blood and lymphatic system disorders
Elevated PSA
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
General disorders
Rapid Weight Loss
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
General disorders
Cyst
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Breathing Difficulty
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory Failure and Coronary Artery Disease
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 3 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Septic Shock
|
0.48%
2/414 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Pneumonia
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Streptococcal Sepsis
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.49%
2/409 • Number of events 2 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Finger Infection
|
0.24%
1/414 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.00%
0/409 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Intestinal Infection
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/414 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
0.24%
1/409 • Number of events 1 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
Other adverse events
| Measure |
Diet & Exercise
n=414 participants at risk
Participants attended an exercise class 3 days/week for 18 months. The exercise program consisted of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's also attended individual and group diet sessions. Each participant's minimum weight loss goal was 10% of baseline body weight.
Diet \& Exercise: Participants attended exercise and diet classes.
|
Attention Control
n=409 participants at risk
The attention control intervention covered an 18-month period delivered in five 1-hour, in-person group meetings at months 1, 3, 6, 9, and 15. Information was also provided in paper packets and in individual telephone sessions every other month.
Attention Control: Participants attended healthy living classes and received health newsletters and phone calls/emails/texts.
|
|---|---|---|
|
Injury, poisoning and procedural complications
Fall
|
17.1%
71/414 • Number of events 85 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
9.0%
37/409 • Number of events 46 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
|
Surgical and medical procedures
Knee Injection
|
8.7%
36/414 • Number of events 44 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
13.7%
56/409 • Number of events 75 • Adverse events were collected from after the participant was randomized until completion of the 18 month intervention.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place